Navigation Links
Pharmaxis Long-Term Safety Study of Bronchitol Completes
Date:6/11/2008

SYDNEY, Australia, June 11 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the 12 month Phase III clinical trial evaluating the safety of Bronchitol in 100 subjects with bronchiectasis has completed.

This 12-month treatment period was an open label extension to a three- month efficacy trial which has already reported, showing that Bronchitol improved quality of life and mucus clearance. The objective of the open label extension is to determine the adverse event profile of Bronchitol following prolonged use.

Following statistical analysis, the results from this second phase of the trial will be reported in July 2008.

Pharmaxis CEO Alan Robertson said following receipt of the study report, Pharmaxis intends filing its first marketing application in Australia for Bronchitol next quarter.

''We are receiving strong demand to continue treatment after participation in the trial has concluded and, where possible, we make this available.''

Bronchitol is being developed as a twice daily inhalation therapy for people with the incurable lung condition bronchiectasis.

It is estimated that more than 600,000 people in the major pharmaceutical markets suffer from bronchiectasis and Pharmaxis expects Bronchitol to be the first targeted medication for this patient group in 20 years, addressing an important medical need. Total U.S. medical care expenditure is US$13,000 per bronchiectasis patient, double that of patients without the disorder; and an increased overall cost to the US health system of US$630 million.

Bronchiectasis is an incurable, degenerative and chronic lung condition that makes breathing difficult through excessive mucus build up in the lungs.

Forward-Looking Statements

The statements contained in this media release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive FDA or other regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors and Other Uncertainties" section of our Form 20-F lodged with the U.S. Securities and Exchange Commission.

CONTACT:

Alan Robertson

Chief Executive Officer

Tel: +61-2-9454-7200

Email: alan.robertson@pharmaxis.com.au

Released through:

Australia:

Virginia Nicholls

Tel: +61-417-610-824

Email: virginia.nicholls@pharmaxis.com.au

United States:

Brandon Lewis, Trout Group

Tel: +1-646-378-2915

Email: blewis@troutgroup.com

Australia:

Felicity Moffatt

Tel: +61-418-677-701

Email: moffattf@healthpr.com


'/>"/>
SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
4. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
5. Horizon Therapeutics Initiates Long-Term Phase 3 Safety Study for Lead Product Candidate HZT-501
6. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
7. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
8. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
11. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... N.C. , Feb. 12, 2016  Clinical Affairs leaders at ... presence in emerging areas of the world. While some companies have ... lag in their clinical activity in countries such as ... China and India ... market products in those countries. --> China ...
(Date:2/12/2016)... 2016   National Community Pharmacists Association (NCPA) ... the following statement today in response to the detailed ... Centers for Medicare & Medicaid Services (CMS) and conducted ... and others: patient advocacy organizations and ... the full CMS analysis. Our initial reaction is that ...
(Date:2/12/2016)... 12, 2016  This month,s issue of the ... takes an in-depth look at various causes and consequences associated ... drug spending, which has generated significant public outrage and ... Laura E. Happe , PharmD, MPH. --> ... PharmD, MPH. --> In 2014 prescription drug ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... Good ... the first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, ... such as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just ...
(Date:2/13/2016)... ... , ... Hidden Cypress in Sun City is the place to be on March 3rd to ... Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting ... pricing on offers. In addition, prizes will be given away and light refreshments will be ...
(Date:2/13/2016)... California (PRWEB) , ... February 13, 2016 , ... Valentine’s ... landing a date for the big day. A great outfit, flawless hair, and a ... they might as well resign themselves to a night at home with Rover. (Actually, ...
(Date:2/13/2016)... Washington, D.C. (PRWEB) , ... February 13, 2016 ... ... joined with Faces and Voices of Recovery, the leading national organization representing the ... paper urging candidates for public office to include Family Recovery in policies addressing ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a ... multitude of reasons. IsoPasta by Isolator Fitness has delved into this niche allowing ... without the high-carb repercussions. IsoPasta has 30 grams of protein and only 7 ...
Breaking Medicine News(10 mins):